{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:28:41Z","timestamp":1787390921237,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["arthroplastyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Arthroplasty"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.arth.2025.11.055","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:51:53Z","timestamp":1764291113000},"page":"2799-2807.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Delayed Administration of Apixaban, but Not Rivaroxaban, Reduces Transfusion Risk Without Increasing Thromboembolic Rates Following Revision Total Hip Arthroplasty"],"prefix":"10.1016","volume":"41","author":[{"given":"Sahil S.","family":"Telang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranit","family":"Kumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mckenzie W.","family":"Culler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Telang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Burdick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay R.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1293-1702","authenticated-orcid":false,"given":"Nathanael D.","family":"Heckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arth.2025.11.055_bib1","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1016\/j.arth.2017.07.028","article-title":"Are revision hip arthroplasty patients at higher risk for venous thromboembolic events than primary hip arthroplasty patients?","volume":"32","author":"Courtney","year":"2017","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.arth.2025.11.055_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.45883","article-title":"Venous thromboembolism in total hip and total knee arthroplasty","volume":"6","author":"Simon","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.arth.2025.11.055_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/1076029618820167","article-title":"Thromboprophylaxis for hip revision arthroplasty: can we use the recommendations for primary hip surgery? A cohort study","volume":"25","author":"Bautista","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.arth.2025.11.055_bib4","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s00264-016-3121-7","article-title":"Revision total hip arthroplasty in the United States: national trends and in-hospital outcomes","volume":"40","author":"Schwartz","year":"2016","journal-title":"Int Orthop"},{"key":"10.1016\/j.arth.2025.11.055_bib5","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.arth.2016.03.031","article-title":"Aspirin can be used as prophylaxis for prevention of venous thromboembolism after revision hip and knee arthroplasty","volume":"31","author":"Deirmengian","year":"2016","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.arth.2025.11.055_bib6","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.arth.2016.01.022","article-title":"Clinical outcomes and costs within 90 days of primary or revision total joint arthroplasty","volume":"31","author":"Nichols","year":"2016","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.arth.2025.11.055_bib7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.artd.2018.02.014","article-title":"What are the incidence and risk factors of in-hospital mortality after venous thromboembolism events in total hip and knee arthroplasty patients?","volume":"4","author":"Shahi","year":"2018","journal-title":"Arthroplast Today"},{"key":"10.1016\/j.arth.2025.11.055_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.arth.2019.08.049","article-title":"Have venous thromboembolism rates decreased in total hip and knee arthroplasty?","volume":"35","author":"Warren","year":"2020","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.arth.2025.11.055_bib9","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1016\/j.arth.2021.03.030","article-title":"Is apixaban safe and effective for venous thromboembolism prophylaxis after primary total hip and total knee arthroplasties?","volume":"36","author":"Rooney","year":"2021","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.arth.2025.11.055_bib10","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.2106\/JBJS.20.02250","article-title":"Venous thromboembolic prophylaxis after total hip and knee arthroplasty","volume":"103","author":"Lieberman","year":"2021","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.arth.2025.11.055_bib11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.5435\/JAAOS-D-15-00760","article-title":"Venous thromboembolism prophylaxis in total hip arthroplasty and total knee arthroplasty patients: from guidelines to practice","volume":"25","author":"Lieberman","year":"2017","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.arth.2025.11.055_bib12","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s11606-020-05904-0","article-title":"Oral anticoagulant utilization in the United States and United Kingdom","volume":"35","author":"Colacci","year":"2020","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.arth.2025.11.055_bib13","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.arth.2023.02.028","article-title":"Safety and efficacy of rivaroxaban in primary total hip and knee arthroplasty","volume":"38","author":"Piple","year":"2023","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.arth.2025.11.055_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-9560-11-10","article-title":"Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring","volume":"11","author":"Mueck","year":"2013","journal-title":"Thromb J"},{"key":"10.1016\/j.arth.2025.11.055_bib15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jjcc.2019.01.001","article-title":"Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese patients with atrial fibrillation (XAPASS)","volume":"74","author":"Ikeda","year":"2019","journal-title":"J Cardiol"},{"key":"10.1016\/j.arth.2025.11.055_bib16","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.2106\/JBJS.K.00521","article-title":"Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty","volume":"94","author":"Jameson","year":"2012","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.arth.2025.11.055_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.arth.2017.08.039","article-title":"Increased incidence of bleeding and wound complications with factor-Xa inhibitors after total joint arthroplasty","volume":"33","author":"Garfinkel","year":"2018","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.arth.2025.11.055_bib18","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1302\/0301-620X.94B11.28955","article-title":"The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme","volume":"94","author":"Lassen","year":"2012","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.arth.2025.11.055_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/srep23726","article-title":"Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials","volume":"6","author":"Ning","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.arth.2025.11.055_bib20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1712746","article-title":"Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty","volume":"378","author":"Anderson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arth.2025.11.055_bib21","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.arth.2025.11.055_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00540-019-02644-2","article-title":"Intraoperative hemorrhage in revision total hip arthroplasty: a retrospective single-center study","volume":"33","author":"Saito","year":"2019","journal-title":"J Anesth"},{"key":"10.1016\/j.arth.2025.11.055_bib23","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.arth.2020.05.013","article-title":"The inaccuracy of ICD-10 coding in revision total hip arthroplasty and its implication on revision data","volume":"35","author":"Lygrisse","year":"2020","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.arth.2025.11.055_bib25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ijrobp.2021.08.007","article-title":"Logistic regression in clinical studies","volume":"112","author":"Zabor","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.arth.2025.11.055_bib26","doi-asserted-by":"crossref","first-page":"768","DOI":"10.5435\/00124635-201112000-00007","article-title":"Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty","volume":"19","author":"Mont","year":"2011","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.arth.2025.11.055_bib27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.arth.2007.05.022","article-title":"Management of bone loss in revision total knee arthroplasty","volume":"22","author":"Huff","year":"2007","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.arth.2025.11.055_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13037-021-00295-5","article-title":"Tranexamic acid lowers transfusion requirements and hospital length of stay following revision total hip or knee arthroplasty","volume":"15","author":"Gianakos","year":"2021","journal-title":"Patient Saf Surg"},{"key":"10.1016\/j.arth.2025.11.055_bib29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000530135","article-title":"Allogeneic blood transfusion and risk of postoperative complications in patients with mild and moderate anemia of any cause? A retrospective cohort study in total revision hip surgery","volume":"51","author":"Uden","year":"2024","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.arth.2025.11.055_bib30","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/phar.1608","article-title":"Retrospective evaluation of postoperative bleeding events in patients receiving rivaroxaban after undergoing total hip and total knee arthroplasty: Comparison with clinical trial data","volume":"35","author":"Wood","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.arth.2025.11.055_bib31","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1177\/1076029618772337","article-title":"Comparison of postoperative bleeding in total hip and knee arthroplasty patients receiving rivaroxaban, enoxaparin, or aspirin for thromboprophylaxis","volume":"24","author":"Lindquist","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.arth.2025.11.055_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/bja\/aeh290","article-title":"Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications","volume":"95","author":"Madjdpour","year":"2005","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.arth.2025.11.055_bib33","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2106\/JBJS.23.00146","article-title":"Increased risk of venous thromboembolism in patients with postoperative anemia after total joint arthroplasty: are transfusions to blame?: are transfusions to blame?","volume":"105","author":"Liu","year":"2023","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.arth.2025.11.055_bib34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.amjcard.2021.11.021","article-title":"Meta-analysis comparing apixaban versus rivaroxaban for management of patients with nonvalvular atrial fibrillation","volume":"166","author":"Mamas","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arth.2025.11.055_bib35","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.hrthm.2024.08.033","article-title":"Apixaban vs rivaroxaban in patients with atrial fibrillation at high or low bleeding risk: a population-based cohort study","volume":"22","author":"Shurrab","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.arth.2025.11.055_bib36","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.2021.21222","article-title":"Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation","volume":"326","author":"Ray","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.arth.2025.11.055_bib37","first-page":"S24","article-title":"Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban","volume":"29","author":"Gong","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.arth.2025.11.055_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-9560-11-11","article-title":"Laboratory assessment of rivaroxaban: a review","volume":"11","author":"Samama","year":"2013","journal-title":"Thromb J"},{"key":"10.1016\/j.arth.2025.11.055_bib39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11239-012-0803-x","article-title":"Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study","volume":"35","author":"Samama","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.arth.2025.11.055_bib40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jth.15563","article-title":"Inter- and intra-individual concentrations of direct oral anticoagulants: the KIDOAC study","volume":"20","author":"Toorop","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.arth.2025.11.055_bib41","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.arth.2025.11.055_bib42","first-page":"705","article-title":"Variation in plasma levels of apixaban and rivaroxaban in clinical routine treatment of venous thromboembolism","volume":"12","author":"Reda","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1016\/j.arth.2025.11.055_bib43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1076029612470489","article-title":"Prethrombotic state and cardiac events in patients with coronary heart disease during noncardiac surgery","volume":"20","author":"Zheng","year":"2014","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.arth.2025.11.055_bib44","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1161\/CIRCULATIONAHA.115.017787","article-title":"Perioperative management to reduce cardiovascular events","volume":"133","author":"Smilowitz","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.arth.2025.11.055_bib45","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.arth.2024.11.020","article-title":"Alarmingly high rates of deep vein thrombosis and pulmonary embolism following closed reduction for dislocated total hip arthroplasty","volume":"40","author":"Telang","year":"2025","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.arth.2025.11.055_bib46","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.3390\/jcm11071754","article-title":"The risk of bleeding and adverse events with clopidogrel in elective hip and knee arthroplasty patients","volume":"11","author":"Wu","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.arth.2025.11.055_bib47","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.arth.2023.02.021","article-title":"Comparison of 90-day adverse events associated with aspirin and potent anticoagulation use for venous thromboembolism prophylaxis: a cohort study of 72,288 total knee and 35,142 total hip arthroplasty patients","volume":"38","author":"Singh","year":"2023","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.arth.2025.11.055_bib48","first-page":"6","article-title":"Time to pay for quality. CMS will partner with premier in trial project to give financial bonuses to hospitals that deliver the best care","volume":"33","author":"Becker","year":"2003","journal-title":"Mod Healthc"}],"container-title":["The Journal of Arthroplasty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883540325015098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883540325015098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:21:50Z","timestamp":1787390510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883540325015098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0883540325015098"],"URL":"https:\/\/doi.org\/10.1016\/j.arth.2025.11.055","relation":{},"ISSN":["0883-5403"],"issn-type":[{"value":"0883-5403","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delayed Administration of Apixaban, but Not Rivaroxaban, Reduces Transfusion Risk Without Increasing Thromboembolic Rates Following Revision Total Hip Arthroplasty","name":"articletitle","label":"Article Title"},{"value":"The Journal of Arthroplasty","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arth.2025.11.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}